Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | RPS6KB1 | P23443 | 12/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 9/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | AKT2 | P31751 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.32 |
| ▸ | SCD | O00767 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14184758 | 0.80 | SCN9A (0.42) | SCN9ARPS6KB1MAPK1HSD17B10AKT1 | |
| SCHEMBL4920729 | 0.77 | HSD17B10 (0.47) | RPS6KB1MAPK1HSD17B10AKT1FAAH | |
| SCHEMBL4923945 | 0.76 | SYK (0.44) | RPS6KB1MAPK1HSD17B10AKT1FAAH | |
| SCHEMBL4931945 | 0.75 | PIK3CA (0.46) | RPS6KB1MAPK1HSD17B10 | |
| SCHEMBL4919626 | 0.72 | MAP3K12 (0.39) | RPS6KB1MAPK1HSD17B10AKT1F10 | |
| SCHEMBL4928603 | 0.68 | HSD17B10 (0.41) | MAPK1HSD17B10FAAH | |
| SCHEMBL4927406 | 0.67 | MKNK1 (0.41) | RPS6KB1AKT1F10 | |
| SCHEMBL13761617 | 0.67 | TRPV1 (0.35) | — | |
| SCHEMBL3880914 | 0.67 | TRPV1 (0.35) | — | |
| SCHEMBL4923903 | 0.67 | RPS6KB1 (0.39) | RPS6KB1AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080124384-A1 | Heteroaryl Substituted Piperazinyl-Pyridine Analogues | NEUROGEN CORPORATION | 2008-05-29 | — | — | US | disclosed |
| US-20080124384-A1 | Heteroaryl Substituted Piperazinyl-Pyridine Analogues | NEUROGEN CORPORATION | 2008-05-29 | — | — | US | disclosed |
| US-20080124384-A1 | Heteroaryl Substituted Piperazinyl-Pyridine Analogues | NEUROGEN CORPORATION | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080124384-A1 | Heteroaryl Substituted Piperazinyl-Pyridine Analogues | PIGO, GPR52, GPR88 | SCN9A 2748/4885RPS6KB1 1053/4885MAPK1 3040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.